Clinical research
Enanta Pharmaceuticals, Inc. announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.
In a Phase III trial, Cosentyx showed a significant and clinically meaningful reduction in disease activity for patients versus placebo.
IXALTIS presents positive results from phase 2 studies for its lead compound Litoxetine, a potential “first in class” treatment for urinary incontinence.
Imugene Limited, a clinical stage immuno-oncology company, announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti-cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.
A multicenter, international, single-arm, Phase II trial of lurbinectedin in progressive Malignant Pleural Mesothelioma (MPM) has been presented at ESMO.
TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo
Evgen Pharma plc announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress in Barcelona.
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
PRESS RELEASES